The ability of SkQ1 eye drops to slow down the cataract development is demonstrated on the senescence-accelerated OXYS rats: the SkQ1 treatment leads to the considerable improvement of the lens condition as compared to the control group. The comparison of the chaperone activities of α-crystallins isolated from the rat lenses did not reveal significant difference between SkQ1-treated and control rats. The contents of major metabolites (23 compounds) in lenses of SkQ1-treated and untreated rats are also very similar, though the concentration of reduced glutathione (GSH) in lenses of SkQ1-treated rats is 12% lower. This difference may be attributed to the reduction of the oxidative stress under action of SkQ1 eye drops, and to the decreased requirement to produce high amounts of this antioxidant.